ClearPoint Neuro, Inc. Announces First-in-Human Cases of
By A Mystery Man Writer
Description
SOLANA BEACH, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling company providing
ClearPoint Neuro Shares Up 16% After Prelim. 4Q Revenue Beats Estimates -January 09, 2024 at 11:00 am EST
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency - 新浪香港
Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson's disease - ScienceDirect
ClearPoint Neuro, Inc. on LinkedIn: ClearPoint Neuro Announces FDA Clearance for Software Version 2.1
ClearPoint Neuro Stock: Potential Inflection Point (NASDAQ:CLPT)
Stock Market News 2021-05-18
Clark Chen's Instagram, Twitter & Facebook on IDCrawl
HealthTech Industry News and Analysis
How fluorescent signals could allow for deeper sensor implants in the brain
Elon Musk's NeuraLink: separating the fact from the fiction
UroMems begins first human study of smart implant for treating SUI
Neuro-navigation Systems Market Size & Growth Report, 2030
ClearPoint Neuro (NasdaqCM:CLPT) Stock Forecast & Analyst Predictions - Simply Wall St
ClearPoint Neuro, Inc. Announces First Procedure Utilizing ClearPoint® 2.0 Software in Europe
from
per adult (price varies by group size)